| Autor: |
Chen, Zhenghao, Simon-Molas, Helga, Cretenet, Gaspard, Valle-Argos, Beatriz, Forconi, Francesco, Schomakers, Bauke V, van Weeghel, Michel, Bryant, Dean, Van Bruggen, Jaco A.C., Peters, Fleur, van der Windt, Gerritje J.W., Kater, Arnon P., Packham, Graham, Eldering, Eric |
| Zdroj: |
Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p3717-3717, 1p |
| Abstrakt: |
Introduction:For chronic lymphocytic leukemia (CLL), especially in the lymph node (LN) setting where cells receive proliferative and pro-survival signals, in-depth studies of altered metabolism and its relationship with therapeutic responses are still lacking. Venetoclax, a BCL-2 inhibitor currently in wide clinical use for CLL, has shown high efficiency yet emerging resistance is a growing clinical problem. In cell line models, induced resistance to Venetoclax was accompanied by profound metabolic changes 1. This is in accordance with our earlier findings on metabolic and apoptotic changes that CLL cells undergo within the LN environment 2. In the current study, we performed RNA sequencing and applied fluxomics with 13C 6-glucose and 13C 5-glutamine to investigate in detail the metabolic routes in LN CLL. This led to studies to manipulate glutamine metabolism in a venetoclax resistance model. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
